Skip to Content
Merck
All Photos(1)

Documents

Safety Information

SML3385

Sigma-Aldrich

Binimetinib

≥98% (HPLC)

Synonym(s):

5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H15BrF2N4O3
CAS Number:
606143-89-9
Molecular Weight:
441.23
MDL number:
MFCD22124525
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C(C1=C(C(F)=C(C2=C1)N=CN2C)NC3=C(C=C(C=C3)Br)F)NOCCO

InChI

1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)

InChI key

ACWZRVQXLIRSDF-UHFFFAOYSA-N

Biochem/physiol Actions

Binimetinib (MEK162, ARRY-162) is an orally active, potent, ATP-uncompetitive MEK1/2 inhibitor (IC50 = 12 nM) that inhibits multiple human tumor growth in xenograft mice in vivo regardless of Kras or Braf mutation (30 or 100 mg/kg/day, 100 mg/kg b.i.d.).

Pictograms

Environment
GHS09

Hazard Statements

H411

Precautionary Statements

P273 - P391 - P501

Hazard Classifications

Aquatic Chronic 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SML3385-VAR:
SML3385-10MG:
SML3385-BULK:
SML3385-50MG:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ethan J Brock et al.
PloS one, 16(5), e0252314-e0252314 (2021-05-29)
Breast ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive ductal carcinoma (IDC). It is still unclear which DCIS will become invasive and which will remain indolent. Patients often receive surgery and radiotherapy, but this early intervention has

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service